|Proteasome modulator 9 SNPs are linked to hypertension in type 2 diabetes families.|
|Jump to Full Text|
|PMID: 21871126 Owner: NLM Status: MEDLINE|
|BACKGROUND: Chromosome 12q24 was recently associated with hypertension. Proteasome Modulator 9 (PSMD9) lies in the 12q24 locus and is in linkage with MODY3, type 2 diabetes (T2D), microvascular and macrovascular pathology, carpal tunnel syndrome, and hypercholesterolemia in Italian families.
AIMS: Our goal was to determine whether PSMD9 is linked to elevated blood pressure/hypertension in T2D families.
METHODS: We characterized the Italian T2D families' members for presence and/or absence of elevated blood pressure (≥ 130/80) and/or hypertension. The phenotypes were described as unknown in all cases in which the diagnosis was either unclear or the data were not available for the subject studied. We tested in the 200 Italians families for the presence of the linkage of the PSMD9 T2D risk single nucleotide polymorphisms (SNPs) IVS3+nt460 A > G, IVS3+nt437 T > C and E197G A > G with elevated blood pressure/hypertension. The non-parametric linkage analysis was performed for this qualitative phenotype by using the Merlin software; the Lod score and correspondent P-value were calculated. Parametric linkage analysis was also performed. For the significant linkage score, 1000 replicates were run to calculate the empirical P-value.
RESULTS: The PSMD9 gene SNPs studied are in linkage with elevated blood pressure/hypertension in our Italian families.
CONCLUSIONS: We conclude that the PSMD9 gene and/or any variant in linkage disequilibrium with the SNPs studied contribute to the linkage to hypertension within our family dataset. This is the first report of PSMD9 linkage to hypertension within the 12q24 locus.
Related Documents :
|1418836 - A randomized, placebo-controlled, double-blind comparison of amlodipine and atenolol in...
2851626 - A plea for more comprehensive blood pressure measurements when evaluating drug treatmen...
2271366 - A comparison of dilevalol and placebo in the management of isolated systolic hypertensi...
7009256 - Once daily beta-blocker in hypertension--oxprenolol slow-release.
8894266 - Diastolic spectrum of left-ventricular hypertrophy: the impact of etiology and coronary...
17381646 - The impact of hypertension and hypertension-related left ventricle hypertrophy on right...
|Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2011-08-28|
|Title: Cardiovascular diabetology Volume: 10 ISSN: 1475-2840 ISO Abbreviation: Cardiovasc Diabetol Publication Date: 2011|
|Created Date: 2011-09-29 Completed Date: 2012-07-03 Revised Date: 2013-06-27|
Medline Journal Info:
|Nlm Unique ID: 101147637 Medline TA: Cardiovasc Diabetol Country: England|
|Languages: eng Pagination: 77 Citation Subset: IM|
|Laboratory of Molecular Genetics of Complex and Monogenic Disorders, Department of Medicine and Cellular & Molecular Physiology and Biostatistics, Penn State University, Hershey, PA, USA. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Diabetes Mellitus, Type 2
Genetic Linkage / genetics
Hypertension / diagnosis, genetics*
Polymorphism, Single Nucleotide / genetics*
Proteasome Endopeptidase Complex / genetics*
|0/PSMD9 protein, human; EC 188.8.131.52/Proteasome Endopeptidase Complex|
Journal ID (nlm-ta): Cardiovasc Diabetol
Publisher: BioMed Central
Copyright ©2011 Gragnoli; licensee BioMed Central Ltd.
Received Day: 10 Month: 8 Year: 2011
Accepted Day: 28 Month: 8 Year: 2011
collection publication date: Year: 2011
Electronic publication date: Day: 28 Month: 8 Year: 2011
Volume: 10First Page: 77 Last Page: 77
Publisher Id: 1475-2840-10-77
PubMed Id: 21871126
|Proteasome Modulator 9 SNPs are linked to hypertension in type 2 diabetes families|
|Claudia Gragnoli123||Email: firstname.lastname@example.org|
1Laboratory of Molecular Genetics of Complex and Monogenic Disorders, Department of Medicine and Cellular & Molecular Physiology and Biostatistics, Penn State University and M. S. Hershey Medical Center, Hershey, PA, USA
2Center for Biotechnology and Department of Biology, Temple University's College of Science & Technology, Philadelphia, PA, USA
3Molecular Biology Laboratory, Bios Biotech Multi-Diagnostic Health Center, Rome, Italy
A recent study has shown that changes in retinal vascular caliber are linked to the chromosome 12q24 locus in a large Caucasian population . Microcirculation is important in determination of hypertension  and retinal vascular changes reflect early microvascular disease and predict cardiovascular events. In two independent samples, the locus 12q24 was also associated with coronary heart disease and hypertension . Thus, the chromosome 12q24 locus carries at least a gene contributing to hypertension. In this locus lies Proteasome Modulator 9 (PSMD9), a coactivator of insulin gene transcription, which is highly expressed in pancreatic islets . PSMD9 is a ubiquitous protein; therefore its biological role may be broad. PSMD9 overexpression cause beta-cell dysfunction and contribute to type 2 diabetes (T2D) . We reported that PSMD9 may rarely cause T2D by unique mutations . We identified a significant linkage of the PSMD9 A/T/G haplotype to late-onset T2D, with the strongest evidence under the recessive model , and to MODY3 under the additive model  in Italians. The contribution of intronic variants to complex disorders is an accepted concept. We recently reported a linkage of the PSMD9 T2D risk single nucleotide polymorphisms (SNPs) with T2D-nephropathy , T2D-neuropathy , retinopathy , carpal tunnel syndrome , hypercholesterolemia , and macrovascular pathology . Given the reported linkage data of PSMD9 within the locus 12q24, and the evidence of linkage with microcirculation within the same locus , PSMD9 is a candidate gene for hypertension. Further, as PSMD9 is linked to T2D, it should be screened to identify any inheritance contributing factors to the T2D-associated phenotypes, of which hypertension is a major player.
In the present study, we aimed at testing the PSMD9 IVS3+nt460, IVS3+nt437, E197G T2D risk SNPs for linkage with elevated blood pressure and/or hypertension in our 200 Italian T2D families.
the subjects were all recruited from center Italy following the Helsinki declaration guidelines. Subjects gave written informed consent. The Penn State College of Medicine Ethical Committee approved the study.
We recruited 200 Italian T2D affected siblings and extended families, including also unaffected members. The families originate from the center of Italy. The members are at least three generations Italians. Identical twins were excluded. These T2D families have been helpful in the whole or as unrelated T2D cases in identifying or excluding diabetes risk genes and/or variants in previous studies [12-24]. We characterized the Italian families for presence/absence of elevated blood pressure/hypertension [presence is considered by blood pressure ≥ 130/80 mmHg in drug-naïve patients or by use of anti-hypertensive medication(s)]. Phenotype is described as unknown if diagnosis is unclear or data are lacking. Most subjects with T2D have elevated blood pressure and few subjects without T2D have elevated blood pressure. The total of the subjects available for the analysis including the ungenotyped parents is 928 (443 founders, 485 non-founders; 467 females, 461 males) with an average family members of 4.62. The diagnostics of hypertension is present in 373 genotyped individuals, with a prevalence of 94.6%.
Via PCR, we amplified the IVS3 PSMD9 region containing the +nt460 A > G and +nt437 C > T SNPs and the exon 5 coding region containing the E197G A > G SNP with specific primers in the affected and unaffected family members. We directly sequenced the PCR products, status post-purification via EXOSAP-IT, on an automated ABI 3730 Sequencer.
We tested in the 200 Italian families for linkage of the PSMD9 SNPs with elevated blood pressure/hypertension. Both non-parametric and parametric linkage analysis for the qualitative phenotype were performed for the three SNPs via Merlin software . Allele frequencies were calculated from the data . Merlin analysed all genetically informative families (n = 129; total subjects = 596) within this dataset, depending on the presence of both genotypes and hypertension phenotype in families whose structure, given the data, was amenable to the linkage tests. The families analysed by Merlin are representative of the population. We previously reported that the PSMD9 SNPs IVS3+nt460, IVS3+nt437, E197G are in strong linkage disequilibrium (LD) . The following parameters were used for the parametric linkage analysis based on the SNPs-cluster, thus eliminating the LD inflation of the linkage signal: disease allele frequency 0.25, dominant model with penetrance for homozygous non-risk allele 0.31 (equal to the prevalence of hypertension in the Italian population), for heterozygous risk allele 1.00, for homozygous risk allele 1.00; recessive model with penetrance for homozygous non-risk allele 0.31, for heterozygous risk allele 0.31, for homozygous risk allele 1.00; additive model with penetrance for homozygous non-risk allele 0.31, for heterozygous risk allele 0.45 and for homozygous risk allele 0.90. All results are reported as LOD scores calculated by Merlin.
For each test performed, to exclude the presence of any false positive in our results, we calculated how many times similar P-values were expected by chance in 1,000 replicates of simulations by using the gene dropping method: this analysis replaces real data with simulated data, while maintaining the pedigree structure, allele frequencies and recombination fraction. These datasets are generated under the null hypothesis of no linkage.
The results of the non-parametric and parametric linkage analysis performed for the qualitative phenotype hypertension are reported in table 1. Both analytical methods have reported significant results with the most significant being for the non-parametric model. The PSMD9 SNP IVS3+nt460 is slightly more significant than the other two SNPs. Under the parametric model analysis, the most significant is the dominant model. The simulation analyses of 1,000 replicates have excluded false positives and establish the validity of the real data.
Our analysis show that the PSMD9 IVS3 +nt460 A > G and +nt437 C > T and exon 5 E197G A > G SNPs studied and/or any variants in LD with them are in linkage with elevated blood pressure/hypertension in our 200 Italian families. The PSMD9 SNPs studied contribute to the linkage of the reported phenotype. It is possible that the recessive and additive models appear less significant than the dominant model, as the disease penetrance value given for the heterozygous state under both models, and for the homozygous state under the additive model, is inferior to 1. Thus, some of the power of the data may be lost. On the other hand, recessive and additive models are still significant as the variants in homozygous state are likely inherited by the affected family subjects more often than expected by the null hypothesis of no linkage and thus contribute to the linkage signal. The limitation of our study is that the linkage may capture the signal from the potential co-inheritance of genetic variants linked to another phenotype and to the underlying T2D that is commonly shared with hypertension; however, as T2D patients have high prevalence of hypertension, virtually all linkage studies performed in T2D may as well mask a linkage with hypertension. In fact, when we statistically analyze only a single phenotype, we cannot protect the results from any potentially known and unknown associated factor with the phenotype under study and from the co-inheritance of genetic variants related to that factor underlying the linkage signal.
The strength of our study resides in the significant data both at the level of non-parametric analysis, which is not vulnerable to miscalculation of allele frequencies and penetrance values, as well as at the level of the parametric analysis, which may suffer from not perfect estimates of allele frequencies and penetrance values.
However, the best statistical power test is the simulation empirical P-value, and in this study all empirical P-values have excluded the possibility of false positives in our data analysis.
These findings have not yet been confirmed in other ethnicities.
The PSMD9 SNPs IVS3+nt460, IVS3+nt437, E197G are significantly linked to elevated blood pressure/hypertension in the Italian T2D family dataset.
PSMD9: Proteasome Modulator 9; SNP: single nucleotide polymorphism; T2D: type 2 diabetes; MODY3: maturity-onset diabetes of the young 3; IVS: intervening sequence (intron)
The authors declare that they have no competing interests.
CG conceived and designed the study, collected the clinical information, performed the statistical analysis and drafted the manuscript. CG also read and approved the final manuscript.
Special thanks go to the Molecular Biology staff of Bios Biotech Multi-Diagnostic Health Center (Rome, Italy), which provided technical support for this study. This study was supported by Penn State College of Medicine.
|Ikram MK,Xueling S,Jensen RA,Cotch MF,Hewitt AW,Ikram MA,Wang JJ,Klein R,Klein BE,Breteler MM,Cheung N,Liew G,Mitchell P,Uitterlinden AG,Rivadeneira F,Hofman A,de Jong PT,van Duijn CM,Kao L,Cheng CY,Smith AV,Glazer NL,Lumley T,McKnight B,Psaty BM,Jonasson F,Eiriksdottir G,Aspelund T,Harris TB,Launer LJ,Taylor KD,Li X,Iyengar SK,Xi Q,Sivakumaran TA,Mackey DA,Macgregor S,Martin NG,Young TL,Bis JC,Wiggins KL,Heckbert SR,Hammond CJ,Andrew T,Fahy S,Attia J,Holliday EG,Scott RJ,Islam FM,Rotter JI,McAuley AK,Boerwinkle E,Tai ES,Gudnason V,Siscovick DS,Vingerling JR,Wong TY,Four novel Loci (19q13, 6q24, 12q24, and 5q14) influence the microcirculation in vivoPLoS GenetYear: 20106e100118410.1371/journal.pgen.100118421060863|
|Thomas MKYK,Tenser MS,Wong GG,Habener JF,Bridge-1, a novel PDZ-domain coactivator of E2A-mediated regulation of insulin gene transcriptionMol Cell BiolYear: 199919849210567574|
|Gragnoli C,Cronsell J,PSMD9 gene variants within NIDDM2 may rarely contribute to type 2 diabetesJ Cell PhysiolYear: 200721256810.1002/jcp.2112717516568|
|Gragnoli C,PSMD9 gene in the NIDDM2 locus is linked to type 2 diabetes in ItaliansJ Cell PhysiolYear: 201022226510.1002/jcp.2195419877155|
|Gragnoli C,PSMD9 is linked to MODY3J Cell PhysiolYear: 2010223120069546|
|Gragnoli C,T2D-nephropathy linkage within 12q24 locusDiabetes Res Clin PractYear: 201192e7310.1016/j.diabres.2011.02.02621439668|
|Gragnoli C,PSMD9 is linked to type 2 diabetes neuropathyJ Diabetes ComplicationsYear: 2011 in press .|
|Gragnoli C,Proteasome Modulator 9 gene is linked to diabetic and non-diabetic retinopathy in T2DOphthalmic GenetYear: 2011 in press .|
|Gragnoli C,Proteasome Modulator 9 and Carpal Tunnel SyndromeDiabetes Res Clin PractYear: 2011 August 19|
|Gragnoli C,Hypercholesterolemia and a candidate gene within the 12q24 locusCardiovasc DiabetolYear: 2011103810.1186/1475-2840-10-3821554682|
|Gragnoli C,Proteasome modulator 9 and macrovascular pathology of T2DCardiovasc DiabetolYear: 2011103210.1186/1475-2840-10-3221496327|
|Gragnoli C,Kir6.2 (KCNJ11) E23K variant in Type 2 Diabetes in ItaliansObesity and MetabolismYear: 200739710.1089/obe.2007.9999|
|Gragnoli C,CHOP T/C and C/T haplotypes contribute to early-onset type 2 diabetes in ItaliansJ Cell PhysiolYear: 200821729110.1002/jcp.2155318680108|
|Gragnoli C,Cronsell J,PPARγ P12A variant in Type 2 Diabetes in ItaliansObesity and MetabolismYear: 2007399|
|Gragnoli C,Cockburn BN,Chiaramonte F,Gorini A,Marietti G,Marozzi G,Signorini AM,Early-onset Type II diabetes mellitus in Italian families due to mutations in the genes encoding hepatic nuclear factor 1 alpha and glucokinaseDiabetologiaYear: 200144132610.1007/s00125010064411692182|
|Gragnoli C,Cronsell J,Meta-analysis of the IPF1 D76N polymorphism in a worldwide type 2 diabetes populationMinerva MedYear: 20079816317592437|
|Gragnoli C,Lindner T,Cockburn BN,Kaisaki PJ,Gragnoli F,Marozzi G,Bell GI,Maturity-onset diabetes of the young due to a mutation in the hepatocyte nuclear factor-4 alpha binding site in the promoter of the hepatocyte nuclear factor-1 alpha geneDiabetesYear: 199746164810.2337/diabetes.46.10.16489313764|
|Gragnoli C,Menzinger Von Preussenthal G,Habener JF,Triple genetic variation in the HNF-4alpha gene is associated with early-onset type 2 diabetes mellitus in a philippino familyMetabolismYear: 20045395910.1016/j.metabol.2004.03.00315281001|
|Gragnoli C,Milord E,Cox N,Worldwide metanalysis of NEUROG3 variants in type 2 diabetesObesity and MetabolismYear: 2006268|
|Gragnoli C,Milord E,Habener JF,Linkage study of the glucagon receptor gene with type 2 diabetes mellitus in ItaliansMetabolismYear: 20055478610.1016/j.metabol.2005.01.02215931615|
|Gragnoli C,Pierpaoli L,Piumelli N,Chiaramonte F,Linkage studies for T2D in Chop and C/EBPbeta chromosomal regions in ItaliansJ Cell PhysiolYear: 200721355210.1002/jcp.2113217620318|
|Gragnoli C,Stanojevic V,Gorini A,Von Preussenthal GM,Thomas MK,Habener JF,IPF-1/MODY4 gene missense mutation in an Italian family with type 2 and gestational diabetesMetabolismYear: 20055498310.1016/j.metabol.2005.01.03716092045|
|Milord E,Gragnoli C,Chromosome 10 locus in linkage to type 2 diabetes in ItaliansObesity and MetabolismYear: 2007344|
|Milord E,Gragnoli C,NEUROG3 variants and type 2 diabetes in ItaliansMinerva MedYear: 20069737317146417|
|Abecasis GR,Cherny SS,Cookson WO,Cardon LR,Merlin--rapid analysis of dense genetic maps using sparse gene flow treesNat GenetYear: 2002309710.1038/ng78611731797|
Non-parametric and Parametric Linkage Analysis of Hypertension in the 200 Italian Families by Merlin software.
|Phenotype||Prevalence||Families||Lod Score||P||Empirical P|
|Dominant Model; SNPs Cluster||94.60%||129||2.282||0.001202||0.000|
|Recessive Model; SNPs Cluster||94.60%||129||1.979||0.002561||0.000|
|Additive Model; SNPs Cluster||94.60%||129||0.926||0.039048||0.000|
Prevalence = phenotype prevalence among the family subjects studied; Families = families number analyzed; Lod score = derived from the non-parametric linkage analysis or the parametric analysis cluster-based by Merlin; P = p-value; Empirical P = p-value derived from 1000 replicates by using the gene dropping method. Hypertension is indicated as presence of blood pressure ≥ 130/80 in absence of medications or presence at least of one anti-hypertensive drug.
Previous Document: Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune chang...
Next Document: The model of rat lipid metabolism disorder induced by chronic stress accompanying high-fat-diet.